Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 82Breast 63Thoracic 53Gynecologic 42Genitourinary 38Lymphoid 32Other hematologic neoplasm 31CNS 31Tumor-Agnostic 28Dermatologic 25Head & Neck 22Sarcoma 20Plasma cell 15Myeloid 9Other solid neoplasm 5Endocrine 4NET 2Classical hematology 1

Conditions

Neuroendocrine Tumors 1Midgut Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Blood Specimen Collection × NET × Clear all
NCT03667092 2025-04-10

GENEBIOLuNET

University Hospital, Toulouse

Phase NA Completed
47 enrolled
EndocrineNET

Midgut Neuroendocrine Tumors

NCT02348749 2025-03-19

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
48 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡